Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine

Phumiamorn, Supaporn; Sato, Hitoshi; Kamiyama, Tsutomu; Kurokawa, Mineo; Shiraki, Kimíyasu

doi:10.1099/vir.0.18692-0

Cited by 9 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MVA, NYVAC, and FP9 are all poxviruses and MVA has also been shown to induce an inflammatory response in vitro (32). Evidence suggests that viral factors and/or interaction of virus with the host are important mediators of cellular immunity to HBsAg (33). In contrast to this study (33), the poxviruses we used are nonreplicative in mammalian cells (34) but are still capable of inducing CMI and Abs to a coadministered protein.…”

Section: Discussionmentioning

confidence: 42%

“…Evidence suggests that viral factors and/or interaction of virus with the host are important mediators of cellular immunity to HBsAg (33). In contrast to this study (33), the poxviruses we used are nonreplicative in mammalian cells (34) but are still capable of inducing CMI and Abs to a coadministered protein. This suggests that the interaction between host and virus is sufficient to enhance immunogenicity, most likely through affecting some form of innate immunity.…”

Section: Discussionmentioning

confidence: 44%

See 1 more Smart Citation

Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity

Hutchings

Gilbert

Hill

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

The presence of both cell-mediated and humoral immunity is important in protection from and clearance of a number of infectious pathogens. We describe novel vaccine regimens using combinations of plasmid DNA, poxvirus and protein to induce strong Ag-specific T cell and Ab responses simultaneously in a murine model. Intramuscular (i.m.) immunization with plasmid DNA encoding the middle Ag of hepatitis B (DNA) concurrently with a commercial hepatitis B virus (HBV) vaccine (Engerix-B) followed by boosting immunizations with both modified vaccinia virus Ankara (MVA) encoding the middle Ag of HBV and Engerix-B induced high levels of CD4+ and CD8+ T cells and high titer Ab responses to hepatitis B surface Ag (HbsAg). Substitution of Engerix-B with adjuvant-free rHBsAg induced similar T cell responses and greatly enhanced Ab levels. Repeated immunizations with recombinant or nonrecombinant MVA mixed with Ag induced higher titers of Abs compared with immunization with either Ag or Engerix-B further demonstrating this novel adjuvant effect of MVA. The poxviruses NYVAC, fowlpox (FP9) and ALVAC, and to a lesser extent, adenovirus, also displayed similar adjuvant properties when used in combination with rHBsAg. The use of poxviruses as an adjuvant for protein to concurrently induce Ag-specific T cells and Abs could be applied to the development of vaccines for many diseases, including HIV and malaria, where both cell mediated and humoral immunity may be important for protection.

show abstract

Section: Discussionmentioning

confidence: 42%

Section: Discussionmentioning

confidence: 44%

Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity

Hutchings

Gilbert

Hill

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…A successful vaccine against pathogens such as HIV-1 will likely require the elicitation of both cellular and humoral immune responses, and strategies that can achieve this are therefore desired. In addition to their ability to stimulate strong immune responses against virus-encoded antigens, live viruses and virus-based vaccines have been shown to provide an adjuvant effect on coimmunized protein antigens (7,9,15,31,52). However, it is not clear if the signals that provide adjuvant activity on the coimmunized protein antigen are the same as those that drive immune responses against virus-encoded antigens.…”

mentioning

confidence: 90%

Humoral Responses against Coimmunized Protein Antigen but Not against Alphavirus-Encoded Antigens Require Alpha/Beta Interferon Signaling

Hidmark

Nordström

Dosenovic

et al. 2006

J Virol

View full text Add to dashboard Cite

“…The hepatitis B transgenic mouse model has been extensively used in the study of viral hepatitis B (27), but mouse strains have demonstrated intra-species variations to vaccine and adjuvants (28). The guinea pig, on the other hand, has been used in previous hepatitis B vaccine studies to investigate the antibody response to novel vaccines (29)(30)(31)(32). These studies describe guinea pigs as highly sensitive to HBsAg and that they produce a significant antibody response to both novel and the standard human hepatitis B vaccine.…”

Section: Discussionmentioning

confidence: 99%

Immunization of Guinea Pigs with Novel Hepatitis B Antigen as Nanoparticle Aggregate Powders Administered by the Pulmonary Route

Muttil

Prego

García-Contreras

et al. 2010

AAPS J

View full text Add to dashboard Cite

Abstract. Novel nanoparticle-aggregate formulations containing recombinant hepatitis B surface antigen (rHBsAg) were administered to the lungs of guinea pigs and antibodies generated to this antigen evaluated. Preparations of dry powders of: (a) rHBsAg encapsulated within poly(lactic-co-glycolic acid) (PLGA)/polyethylene glycol (PEG) nanoparticles (antigen nanoparticles, AgN SD ), (b) rHBsAg in a physical mixture with blank PLGA/PEG nanoparticles (antigen nanoparticle admixture (AgNA SD ), and (c) rHBsAg encapsulated in PLGA/PEG nanoparticles plus free rHBsAg (antigen nanoparticles and free antigen), were generated by spray drying with leucine. Control groups consisted of alum with adsorbed rHBsAg (AlumAg); reconstituted suspensions of spray-dried rHBsAg-loaded PLGA/PEG nanoparticles with leucine; and rHBsAg-loaded PLGA/PEG nanoparticles (AgN). Control preparations were administered by intramuscular injection; AgN was also spray instilled into the lungs. The IgG titers were measured in the serum for 24 weeks after the initial immunization; IgA titers were measured in the bronchio-alveolar lavage fluid. While the highest titer of serum IgG antibody was observed in guinea pigs immunized with AlumAg administered by the IM route, animals immunized with powder formulations via the pulmonary route exhibited high IgA titers. In addition, guinea pigs immunized with AgNA SD via the pulmonary route exhibited IgG titers above 1,000 mIU/ml in the serum (IgG titers above 10 mIU/ml is considered protective). Thus, the disadvantages observed with the existing hepatitis B vaccine administered by the parenteral route may be overcome by administering them as novel dry powders to the lungs. In addition, these powders have the advantage of eliciting a high mucosal immune response in the lungs without traditional adjuvants.

show abstract

Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine

Cited by 9 publications

References 29 publications

Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity

Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity

Humoral Responses against Coimmunized Protein Antigen but Not against Alphavirus-Encoded Antigens Require Alpha/Beta Interferon Signaling

Immunization of Guinea Pigs with Novel Hepatitis B Antigen as Nanoparticle Aggregate Powders Administered by the Pulmonary Route

Contact Info

Product

Resources

About